Effect of Laser Acupoints on Fallopian Tube Obstruction
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age20-35
SponsorKafrelsheikh University
About this trial
This study aims to determine the efficacy of laser acupoint therapy on treating fallopian tube obstruction.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Women aged 20-35 years - nulliparous.
Women diagnosed with fallopian tube obstruction.
Body mass index less than 30 kg/m2.
Consent to participate in the study.
Disqualifiers
Currently pregnant or breastfeeding.
History of pelvic surgery within the past year.
Presence of severe systemic diseases such as active cancer or severe cardiovascular diseases.
History of allergic reactions or adverse responses to acupuncture or laser therapies.
Trial design
Design model
Parallel
Treatments tested in this trial
Laser acupoints therapy + Standard care
Other interventionPatients will receive laser acupoints therapy addition to standard care.
Standard care
Other interventionPatients will receive placebo laser acupoints therapy in addition to standard care.
Treatment groups
36 Participants
are divided into 2 treatment groupsGroup A: Study Group (Group A)Experimental treatment 1 intervention
Group B: Control Group (Group B)Placebo comparator 1 intervention
Trial outcomes
Primary outcomes
1
Tubal patency
Hysterosalpingography (HSG) will be used to assess tubal patency. It is a radiographic technique where a contrast material is injected into the uterine cavity, and X-ray images are taken to evaluate the shape of the uterus and the status of the fallopian tubes. HSG will be applied before the treatment and again three months post-treatment to evaluate changes in tubal patency HSG will be applied before treatment and after 3 months post-treatment.
Time frame
3 months post-treatmentSecondary outcomes
1
Anti-Müllerian Hormone (AMH) Test
A blood test will be used to measure the level of Anti-Müllerian Hormone (AMH), which is an indicator of the remaining quantity of eggs and ovarian function. This test will be conducted before the treatment and at the third month of treatment to monitor any changes in ovarian reserve.
Time frame
3 months post-treatment2
Quantitative Pregnancy Test
A blood test that will be measured the specific level of Human Chorionic Gonadotropin (hCG), which is produced during pregnancy. This test will be performed every month.
Time frame
3 months post-treatmentSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov